What Is Melanotan-2? Definition and What Research Reports

Plain-language definition

Melanotan-2 is a laboratory-made peptide modelled on a natural human hormone fragment called alpha-melanocyte-stimulating hormone (α-MSH). Because α-MSH is the signal that tells pigment cells in skin to make more melanin, chemists built a more stable, longer-acting copy of it to study that signalling pathway. Melanotan-2 is that copy: a small ring-shaped chain of amino acids that switches on the same family of cell-surface receptors, called melanocortin receptors. It is a research compound and an unapproved substance in consumer markets, not a licensed medicine, and the published literature on it consists mainly of animal experiments plus scattered human case reports.

What melanotan-2 is in biochemical terms

Melanotan-2 is commonly described as a cyclic heptapeptide analogue of α-MSH, abbreviated MT-II or MTII in the scientific literature. The cyclisation (a bridge between two side chains within the chain) and the substitution of a D-amino acid make the molecule resistant to the enzymes that rapidly break down natural α-MSH, which is why it is used as a pharmacological tool rather than the native hormone.

Functionally, melanotan-2 is a non-selective melanocortin receptor agonist. The melanocortin receptor family includes:

• MC1R — expressed on melanocytes; the receptor most associated with melanin synthesis and pigmentation.
• MC3R and MC4R — expressed in the central nervous system; studied in relation to energy balance, food intake and body composition.
• MC2R — the adrenal ACTH receptor.
• MC5R — associated with exocrine gland function.

Because melanotan-2 does not confine its activity to MC1R, studies that use it as a tool compound often describe effects that extend well beyond pigmentation — which is the main reason the peptide appears in obesity, behaviour and oncology research rather than only in dermatology research.

Regulatory framing of the term

Melanotan-2 has no marketing authorisation as a medicine in the United States, the United Kingdom, the European Union or Australia. It circulates as a research-use-only (RUO) chemical, and national regulators have issued public warnings about unlicensed products sold under the name. RUO labelling means a substance is intended for laboratory investigation and has not been evaluated for human safety, purity or potency by a drug regulator.

Two structurally related melanocortin agonists are approved medicines, and confusing them with melanotan-2 is one of the most common errors in popular writing:

• Afamelanotide — a linear α-MSH analogue approved as an implant for a rare light-sensitivity disorder, erythropoietic protoporphyria. It is sometimes called "melanotan-1" in non-scientific sources, a label that does not appear in its regulatory documentation.
• Bremelanotide — a metabolite-derived melanocortin agonist approved for hypoactive sexual desire disorder in premenopausal women.

Melanotan-2 is neither of these. Sharing a receptor family does not mean sharing a safety profile, a dose range or an approved indication.

How the term is used in peptide research

In the primary literature, "MT-II" usually appears as a pharmacological probe: researchers administered it to activate melanocortin receptors and then measured what changed. The peptide is valued in that role precisely because it is potent and long-acting, which makes receptor activation easier to detect than with native α-MSH.

Three research contexts where the term appears

1. Energy balance and adipose tissue. A 2007 rodent study examined the effects of the melanocortin agonist MT-II on subcutaneous and visceral adipose tissue, treating the compound as a way to interrogate melanocortin control of fat depots (PMID 17567964). An earlier rat study reported that peripherally administered MTII reduced fat without invoking apoptosis, meaning the fat loss the authors observed was not explained by programmed cell death in adipocytes (PMID 12834806).
2. Behavioural pharmacology. A 2003 paper assessed the aversive consequences of acute and chronic administration of MTII, testing whether reductions in food intake reflected a genuine satiety signal or an aversive state in the animals (PMID 12704398). This kind of control experiment is a standard part of appetite research and illustrates how the compound is used to ask mechanistic, not therapeutic, questions.
3. Tumour biology. A 2020 study reported that topical MTII therapy suppressed melanoma in an experimental model, with the authors attributing the effect to PTEN upregulation and cyclooxygenase-II inhibition (PMID 31968661). The study describes a laboratory model of tumour suppression, not a treatment for people.

Where the term is misused

• As a synonym for "tanning peptide." Popular sources reduce melanotan-2 to a cosmetic tanning agent, which ignores that the same molecule acts on central MC3R/MC4R pathways studied in appetite and behaviour work (PMID 12704398).
• As interchangeable with afamelanotide. The "melanotan-1 versus melanotan-2" framing implies two versions of one approved drug. They are different molecules with different regulatory status.
• As "studied for fat loss in humans." The adipose-tissue findings above were rodent findings, and the researchers framed them as mechanistic (PMID 17567964, PMID 12834806).
• As "anti-cancer." A topical model of melanoma suppression in one 2020 report is not evidence of a human cancer therapy (PMID 31968661).
• As a quality-controlled product. Material sold under the name is not subject to pharmaceutical identity, purity or sterility standards.

Adverse Events in the Literature: What Studies Report

The human safety literature on melanotan-2 is built from case reports rather than controlled trials, so it describes events that occurred in individuals and cannot establish how often anything happens. A 2020 case report and literature review in CEN Case Reports described renal infarction as a possible consequence of melanotan II exposure, and the authors reviewed previously published reports alongside their own case (PMID 31953620). The report is notable because it concerns a vascular event, a category not predicted by the pigmentation framing that dominates popular descriptions of the peptide.

In animals, the aversive-consequences study examined whether MTII produced an unpleasant internal state after acute and chronic administration — an adverse-effect question posed inside an efficacy experiment (PMID 12704398). The 2003 fat-loss study in rats specifically reported that the reduction in fat it observed occurred without apoptosis, which the researchers presented as evidence about mechanism rather than about tolerability (PMID 12834806).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or substance. Nothing here describes a protocol, and no dose from any cited study is presented as applicable to humans.

Related terms

Limitations of the evidence base

Readers comparing sources should note three structural features of this literature. First, the mechanistic studies are predominantly rodent studies, and species differences in melanocortin signalling and metabolism are substantial (PMID 17567964). Second, the human data are case reports, which describe outcomes in single individuals and are vulnerable to confounding by unverified product composition (PMID 31953620). Third, the tumour-model work used a topical route in an experimental system, so its findings do not transfer to other routes or to clinical oncology (PMID 31968661). A glossary definition can state what melanotan-2 is with reasonable confidence; statements about what it does in people remain poorly characterised.

References

• Melanotan II: a possible cause of renal infarction: review of the literature and case report (CEN Case Reports, 2020)
• Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII (International Journal of Obesity and Related Metabolic Disorders, 2003)
• The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents (The Journal of Pharmacology and Experimental Therapeutics, 2007)
• Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition (International Journal of Molecular Sciences, 2020)
• MTII administered peripherally reduces fat without invoking apoptosis in rats (Physiology & Behavior, 2003)